Hanna Peltonen

Title: Innovations in Gene Therapy: The Contributions of Hanna Peltonen

Introduction

Hanna Peltonen is a notable inventor based in Kuopio, Finland. She has made significant contributions to the field of gene therapy, particularly in the development of methods to ensure the safety and efficacy of viral gene therapy vectors. Her work addresses critical challenges in the manufacturing process of these vectors, which are essential for various therapeutic applications.

Latest Patents

Hanna Peltonen holds a patent for a "Gene therapy vector contamination assay." This innovative assay is designed to detect the presence of replication-competent viruses that may inadvertently form during the manufacturing of viral gene therapy vectors. The traditional methods of detection involve complex procedures that can be time-consuming and less sensitive. Peltonen's approach utilizes digital PCR, which has proven to be faster and significantly more sensitive, capable of detecting as few as seven replication-competent adenoviruses in a sample of 3×10 assay cells. This advancement not only streamlines the testing process but also enhances the safety of gene therapy products.

Career Highlights

Hanna Peltonen is currently associated with Trizell Limited, where she continues to innovate in the field of gene therapy. Her expertise and dedication to research have positioned her as a key figure in the development of safer and more effective gene therapy solutions.

Collaborations

Hanna collaborates with talented colleagues, including Jenni Mykkanen and Minna Hassinen, who contribute to her research efforts and the advancement of gene therapy technologies.

Conclusion

Hanna Peltonen's work in gene therapy represents a significant leap forward in ensuring the safety of viral vectors used in therapeutic applications. Her innovative patent and ongoing research efforts are paving the way for more effective treatments in the future.